Andria Rakotomalala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andria Rakotomalala has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Mannan
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
15 shared publications - Adjanie Patabendige
Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
15 shared publications - Alicia M. Douglas
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
15 shared publications - Brett Nixon
University of Newcastle
15 shared publications - Bryan W. Day
Sid Faithful Brain Cancer Research Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006 Australia
15 shared publications - Carl Koschmann
Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan
15 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma